Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
about
Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementNeuromyelitis optica: clinical features, immunopathogenesis and treatment.Risk evaluation and monitoring in multiple sclerosis therapeutics.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Induction therapy for patients with multiple sclerosis: why? When? How?Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Dimethyl fumarate (BG-12) for the treatment of multiple sclerosis.Management of disease-modifying treatments in neurological autoimmune diseases of the central nervous system.The current role of mitoxantrone in the treatment of multiple sclerosis.The transition from first-line to second-line therapy in multiple sclerosis.Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study.Long-term treatment risks in multiple sclerosis: risk knowledge and risk perception in a large cohort of mitoxantrone-treated patients.Drugs approved for the treatment of multiple sclerosis: review of their safety profile.[Current immunotherapy of multiple sclerosis].Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis
P2860
P921
Q26796643-DDB0B56C-F69B-4E38-A508-A2EC2AF6E7D5Q30785267-78E55AB1-A082-496E-9BC5-BF0C262DED9EQ34513188-D24DEA5B-C7EA-4DF0-BFAD-C235BC4E7EF8Q35052199-4DC9C032-7B83-4BD7-B9D2-76455FF04A36Q36648907-A81E9C85-164A-43EE-A903-BDA9A8CD7862Q36923587-2699F510-3844-48FC-8731-56D2B8174A8DQ36982030-17E8B648-D318-4B76-BB3D-5C2EEA8BB288Q37615119-F7BCC481-C5B2-4F4A-88BB-0D30FCF3F6E2Q38127463-B21FF011-2FCD-4F9E-92D0-CDB37C2AD6B7Q38172961-E7944146-4E43-4973-9F72-261F12F5509FQ38212259-3A7DCFCC-B4AD-4B01-A8B0-07BC100F410FQ41014662-1D622B27-4309-4FF4-B459-2B2B63ECCBFEQ41318551-9B6A6AE8-EFDF-42EB-9E31-0C6959A366A2Q45354300-D9878F2A-B315-424C-A10D-1EAF24C89DE8Q47868767-A3A7693E-C131-4A17-928E-5DEFEB029344Q52863422-A2A5C2D8-5A54-4B82-8E5F-9E0DE23A4E71Q58573155-38789CDC-8570-4495-8532-381DFDC77A7B
P2860
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Incidence of therapy-related a ...... sclerosis patients in Germany
@ast
Incidence of therapy-related a ...... sclerosis patients in Germany
@en
type
label
Incidence of therapy-related a ...... sclerosis patients in Germany
@ast
Incidence of therapy-related a ...... sclerosis patients in Germany
@en
prefLabel
Incidence of therapy-related a ...... sclerosis patients in Germany
@ast
Incidence of therapy-related a ...... sclerosis patients in Germany
@en
P2093
P2860
P50
P921
P356
P1476
Incidence of therapy-related a ...... sclerosis patients in Germany
@en
P2093
Andrew Chan
Anke Stroet
Claudia Hemmelmann
Holger Nückel
Michaela Starck
Paul Friedemann
Peter Flachenecker
P2507
P2860
P356
10.1177/1756285611433318
P577
2012-03-01T00:00:00Z